Abstract
Introduction. The results of experimental studies indicate the growth factors, in particular the vascular endothelial growth factor, around the hematoma already at the beginning of hemorrhagic stroke.
 The aim of the study: to find out the features of vascular endothelial growth factor expression in patients with hemorrhagic stroke depending on the disease severity.
 Research metods. 53 patients with hemorrhagic stroke were examined. The control group - 25 people with hypertension without dyscirculatory disorders of cerebral circulation.
 The level of neurological deficit was assessed using the National Institute of Health Stroke Scale (NIHSS).
 Vascular endothelial growth factor (VEGF) in the blood was determined on the 1st, 5th and 21st days of the acute stroke period by enzyme-linked immunosorbent assay (ELISA) (test kits of the company "Biosourse" (USA)). The research results were analyzed by the method of variational statistics using the program "STATISTICA 6.0" (StatSoft, USA).
 Results and discussion. With a mild degree of severity, the content of VEGF in the blood is significantly lower on the 1st and 5th days of the acute period compared to the control group. This may be one of the factors contributing to the development of a hemorrhagic stroke. An increase in VEGF in the first days of the disease can be a marker of the serious condition of patients with hemorrhagic stroke. VEGF levels on the 5th and 21st days are highest in mild cases, and lowest in severe cases. The increased synthesis of VEGF in case of a mild stroke indicates a more adequate response of the endothelium to damage.
 Conclusions. A marker of a mild hemorrhagic stroke can be low VEGF levels in the first days of the disease and their significant increase at the end of the previous period. High VEGF in the blood at the beginning of the disease, and relatively lower indicators (compared to a mild course) at the end of the previous period are associated with the severe condition of patients with hemorrhagic stroke.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
